SCHEMBL2223167

SCHEMBL2223167

CC1(C)CCC(C)(C)c2cc(-c3csc(N4CCC(NCCCO)C4)n3)ccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.39
NPC1 O15118 9/20 0.39
ALDH1A1 P00352 2/20 0.39
CTSL P07711 3/20 0.38
CTSB P07858 3/20 0.38
CTSS P25774 3/20 0.38
PTPN1 P18031 1/20 0.38
PTPN6 P29350 1/20 0.38
CDC25A P30304 1/20 0.38
RARB P10826 1/20 0.38
RARG P13631 1/20 0.38
SMN1; SMN2 Q16637 11/20 0.38
CYP1A2 P05177 4/20 0.37
CYP2C9 P11712 4/20 0.37
CYP2C19 P33261 4/20 0.37
MAPT P10636 4/20 0.37
HPGD P15428 2/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2223158 1.00 RAB9A (0.39) RAB9ANPC1ALDH1A1CTSLCTSB
SCHEMBL12515999 0.97 RAB9A (0.38) RAB9ANPC1ALDH1A1CTSLCTSB
SCHEMBL2224845 0.95 CTSL (0.38) RAB9ANPC1ALDH1A1CTSLCTSB
SCHEMBL12516993 0.94 RAB9A (0.40) RAB9ANPC1ALDH1A1CTSLCTSB
SCHEMBL2226835 0.94 PTPN1 (0.41) RAB9ANPC1ALDH1A1CTSLCTSB
SCHEMBL2227536 0.92 CTSL (0.37) RAB9ANPC1ALDH1A1CTSLCTSB
SCHEMBL2223678 0.92 PTPN1 (0.41) RAB9ANPC1ALDH1A1CTSLCTSB
SCHEMBL2225956 0.91 PTPN1 (0.39) RAB9ANPC1ALDH1A1CTSLCTSB
SCHEMBL2223947 0.91 PTPN1 (0.40) RAB9ANPC1ALDH1A1CTSLCTSB
SCHEMBL12515980 0.91 PTPN1 (0.40) RAB9ANPC1ALDH1A1CTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8907098-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2014-12-09 US disclosed
US-8907098-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2014-12-09 US disclosed
EP-2513066-A1 SPHINGOSINE KINASE INHIBITORS Merck Patent GmbH (DE) 2012-10-24 EP disclosed
US-20120252815-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
US-20120252815-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
WO-2011082732-A1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252815-A1 INHIBITORS OF SPHINGOSINE KINASE SPHK1, S1PR3, SPHK2 RAB9A 1129/4885NPC1 818/4885ALDH1A1 4560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.